Compare Figure Technology Solutions Inc. Class A Common Stock (FIGR) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figure Technology Solutions Inc. Class A Common Stock vs Tango Therapeutics Inc. — how do they compare? Figure Technology Solutions Inc. Class A Common Stock trades at $25 (market cap $6.11B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Figure Technology Solutions Inc. Class A Common Stock is the larger of the two by market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Figure Technology Solutions Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Figure Technology Solutions Inc. Class A Common Stock for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| FIGR | TNGX | |
|---|---|---|
Market Cap | $6.11B | $3.75B |
Volume | 5,025,604 | 9,619,106 |
Sector | Financials | Health |
52-Week High | $73.91 | $32.90 |
52-Week Low | $24.91 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $6.15B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIGR trades at $27.25, down 4.25% over 24 hours, with a bearish technical signal from moving averages. The company reported strong fundamentals: Q2 2026 EPS beat expectations at $0.37, revenue grew to $509.30M in 2025, and net income margin improved to 33.83% in 2026. Recent news highlights the Kiavi acquisition and partnership with Sierra to enhance AI-driven lending capabilities, supporting growth in loan volumes.
Wall Street maintains a bullish outlook with a consensus price target of $50.00, implying significant upside. However, risks include recent earnings misses in Q4 2025 and Q1 2026, negative operating cash flow projected for 2026, and competitive pressures in the lending infrastructure space. The stock's high P/E of 28.52 warrants caution amid growth execution uncertainties.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Figure Technology Solutions Inc. Class A Common Stock
Figure Technology Solutions operates a blockchain-native capital marketplace. Its platform supports loan origination, funding, sale, and trading of tokenized assets, along with digital-asset infrastructure and services.
Read more on FIGR →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
